Stay up-to-date with the Jerome Lejeune Foundation

A Potential New Drug Treatment for a Rare Disorder: Funding from the Jerome Lejeune Foundation has assisted researchers in identifying a drug to treat MECP2 duplication syndrome. Findings were published in Molecular Psychiatry on September 8, 2015. The disorder occurs in boys and displays a wide variety of symptoms, including low muscle tone, developmental delays, recurrent respiratory infections, speech abnormalities, seizures, autistic behaviors, and potentially severe intellectual disability.

Shutting Down the Extra 21st Chromosome: Researchers at Elixergen LLC published remarkable research on August 31, 2015 in a paper called Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures. Their research showed the possibility of introducing ZSCAN4, a gene responsible for genomic stability, into cell cultures of individuals with Down syndrome and Edward syndrome. When those cells divided, 41% of the cells had no extra chromosome.

A Medical and Pedagogical Center in Dubai: In October 2015, the Jerome Lejeune Foundation opened a medical clinic in Dubai that will provide care and therapy to children under 15 years of age with learning, language, or developmental disorders which require a multidisciplinary approach.

JLF USA President Appointed to NORD Bioethics Committee: Mark Bradford, president of the Jerome Lejeune Foundation USA, has been appointed to the Bioethics Committee of the National Organization for Rare Disorders.

Jerome Lejeune: To The Least of These My Brothers and Sisters: The documentary on Dr. Jerome Lejeune will be shown three times in October, including at the JPII Inter-Faith Film Festival in Miami, FL, in Philadelphia, and in Lincoln, NE. Call us for information if you live in those areas and are interested in attending.